CD137/OX40 Bispecific Antibody Induces Potent Antitumor Activity that Is Dependent on Target Coengagement
Published version of a preprint
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Abstract Following the success of immune checkpoint blockade therapy against cancer, agonistic antibodies targeting T-cell costimulatory pathways are in clinical trials. The TNF superfamily of receptors (TNFRSF) members CD137 and OX40 are costimulatory receptors that stimulate T-cell proliferation and activation upon interaction with their cognate ligands. Activating CD137 and OX40 with agonistic mAbs stimulates the immune system due to their broad expression on CD4+ and CD8+ T cells and natural killer cells and has antitumor effects in preclinical models. Most TNFRSF agonist antibodies require crosslinking via Fcγ receptors (FcγR), which can limit their clinical activity. FS120 mAb2, a dual agonist bispecific antibody targeting CD137 and OX40, activated both CD4+ and CD8+ T cells in an FcγR-independent mechanism, dependent on concurrent binding. A mouse surrogate version of the bispecific antibody displayed antitumor activity in syngeneic tumor models, independent of T regulatory cell depletion and of FcγR interaction, but associated with peripheral T-cell activation and proliferation. When compared with a crosslink-independent CD137 agonist mAb, the FS120 surrogate induced lower liver T-cell infiltration. These data support initiation of clinical development of FS120, a first-in-class dual agonist bispecific antibody for the treatment of human cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“however, mAbs targeting and inhibiting either OX40 and CD137 individual result in poor efficacy and/or promote liver toxicity.”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Gaspar et al., 2020
In the citing paper
“Dual agonistic bispecific antibodies binding to both OX40 and CD137, however, promote FcRγ-crosslinking-independent anti-tumor activity and moreover limit liver injury; clinical trials utilizing these dual agonistic bi-specific antibodies are ongoing (Gaspar et al., 2020).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Gaspar et al., 2020
Citations
Cites
Bruhns, P., Iannascoli, B., England, P., Mancardi, D. A., Fernandez, N., Jorieux, S., & Daëron, M. (2009) · Blood · doi:10.1182/blood-2008-09-179754 · Cited by 1,479
Thommen, D. S., & Schumacher, T. N. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.012 · Cited by 1,299 · cited 3×
“Activating TILs with agonist antibodies against OX40 and CD137 has the potential to unleash existing antitumor immune responses and reduces tumor growth and increases survival in several syngeneic tumor models (39, 40).”
BackgroundTHE COVALENT STRUCTURE OF AN ENTIRE γG IMMUNOGLOBULIN MOLECULE
Edelman, G. M., Cunningham, B. A., Gall, W. E., Gottlieb, P. D., Rutishauser, U., & Waxdal, M. J. (1969) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.63.1.78 · Cited by 901
Selby, M. J., Engelhardt, J. J., Quigley, M., Henning, K. A., Chen, T., Srinivasan, M., & Korman, A. J. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0013 · Cited by 857 · cited 1×
“The depletion of intra-tumoral 13 Tregs, described as the mechanism of action of OX40 and CD137 antibodies in mouse syngeneic 14 tumor models, may not be as effective in human cancers (6,7,43) and may also result in the 15 depletion of the very same cells the OX40 and CD137 antibodies aim to stimulate (15).”
BackgroundProperties of mouse and human IgG receptors and their contribution to disease models
Bruhns, P. (2012) · Blood · doi:10.1182/blood-2012-01-380121 · Cited by 847 · cited 1×
“Limited availability of FcR-expressing cells in the tumor microenvironment of human 11 cancers and low affinity interaction between FcRs and the Fc region of IgG antibodies (41) could 12 result in sub-optimal crosslinking of these agonist antibodies (42).”
BackgroundNext generation of immune checkpoint therapy in cancer: new developments and challenges
Marin-Acevedo, J. A., Dholaria, B., Soyano, A. E., Knutson, K. L., Chumsri, S., & Lou, Y. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0582-8 · Cited by 804
OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients
Curti, B. D., Kovacsovics-Bankowski, M., Morris, N., Walker, E., Chisholm, L., Floyd, K., Walker, J., Gonzalez, I., Meeuwsen, T., Fox, B. A., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4174 · Cited by 496 · cited 2×
“The induction of T cell proliferation by OX40 and CD137 agonist antibodies in vitro and in vivo is 7 described in both preclinical models and in the clinic (11,34).”
BackgroundResults from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody
Segal, N. H., Logan, T. F., Hodi, F. S., McDermott, D., Melero, I., Hamid, O., Schmidt, H., Robert, C., Chiarion-Sileni, V., Ascierto, P. A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1272 · Cited by 424 · cited 3×
“9) induces severe transaminitis at 20 doses higher than 1 mg/kg resulting in two hepatotoxicity-related deaths (13) and utomilumab (PF21 05082566, clone MOR7480.”
BackgroundInfluentialEngagement of the OX-40 Receptor In Vivo Enhances Antitumor Immunity
Weinberg, A. D., Rivera, M.-M., Prell, R., Morris, A., Ramstad, T., Vetto, J. T., Urba, W. J., Alvord, G., Bunce, C., & Shields, J. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.4.2160 · Cited by 387
The promise and challenges of immune agonist antibody development in cancer
Mayes, P. A., Hance, K. W., & Hoos, A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.75 · Cited by 355 · cited 1×
“Additionally, interaction with FcRs mediates antibody effector functions such as ADCC 32 and ADCP and could lead to the depletion of the tumor-specific T cells that would be activated by 33 these antibodies (18).”
Background
Research works printed but not linked: 1
- Segal, 2018, Phase I study of single-agent utomilumab (PF-05082566), a 4-1BB/CD137 agonist, in patients with advanced cancer, Clin Cancer Res, 24, 1816, 10.1158/1078-0432.CCR-17-1922 · DOI · Paper page
Cited by
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648
The present and future of bispecific antibodies for cancer therapy
Klein, C., Brinkmann, U., Reichert, J. M., & Kontermann, R. E. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00896-6 · Cited by 490
“This activity required co-engagement of both receptors for efficient immune cell activation and antitumour activity, supporting the concept of dual targeting of co-stimulatory receptors with tetravalent bsAbs to induce efficient receptor clustering and activation 238 .”
Emerging new therapeutic antibody derivatives for cancer treatment
Jin, S., Sun, Y., Liang, X., Gu, X., Ning, J., Xu, Y., Chen, S., & Pan, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00868-x · Cited by 459
The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy
Claus, C., Ferrara, C., & Klein, C. (2023) · mAbs · doi:10.1080/19420862.2023.2167189 · Cited by 126
“Bi-, tri- or tetra-specific IgG-based drugs typically display modifications of the Fc to abrogate binding and subsequently crosslinking via Fcγ-receptors while maintaining binding to natal Fc receptor (FcRn) to provide antibody-like pharmacokinetics (PK).(32,36,45,46,61,63,64,66,69,70) The abolishment of Fcγreceptor-b…”
BackgroundBispecific antibodies in cancer therapy: Target selection and regulatory requirements
Sun, Y., Yu, X., Wang, X., Yuan, K., Wang, G., Hu, L., Zhang, G., Pei, W., Wang, L., Sun, C., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.05.023 · Cited by 125
Metadata
- Authors
- Gaspar, M., Pravin, J., Rodrigues, L., Uhlenbroich, S., Everett, K. L., Wollerton, F., Morrow, M., Tuna, M., & Brewis, N.
- Affiliations
- F-star (United Kingdom) (GB)
- Venue
- Cancer Immunology Research
- Published
- 2020-06-01
- Volume
- 8
- Issue
- 6
- Pages
- 781-793
- ISSN
- 2326-6066 (ISSN-L)
- 2326-6074
- OpenAlex
- W3015859054
- Cited by
- 58
- References
- 49
- Citations by year
- 2026: 7 · 2025: 5 · 2024: 4 · 2023: 12 · 2022: 16 · 2021: 13 · 2020: 1
- FWCI
- 3.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Immunology Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Melanie Medcalf and Edouard Souteyrand (CD137, FS120)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- 4-1BB, OX40, bispecific antibodies, agonistic antibodies, T cell costimulation, anticancer activity, T cell activation, cancer immunotherapy
- MeSH terms
- Animals, Colonic Neoplasms, Female, Humans, Immunotherapy, Killer Cells, Natural, Lymphocyte Activation, Mice, Inbred BALB C, Tumor Cells, Cultured, Apoptosis, Antibodies, Bispecific, Xenograft Model Antitumor Assays, Cell Proliferation, T-Lymphocytes, Regulatory, Mice, Tumor Necrosis Factor Receptor Superfamily, Member 9, Receptors, OX40
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CD137/OX40 Bispecific Antibody Induces Potent Antitumor Activity that Is Dependent on Target Coengagement. https://app.cochat.ai/papers/10.1158/2326-6066.cir-19-0798
- The paper
- Gaspar, M., Pravin, J., Rodrigues, L., Uhlenbroich, S., Everett, K. L., Wollerton, F., Morrow, M., Tuna, M., & Brewis, N. (2020). CD137/OX40 Bispecific Antibody Induces Potent Antitumor Activity that Is Dependent on Target Coengagement. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-19-0798
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.